Peripheral arterial disease (PAD) is a marker for severe systemic atherosclerosis. Patients with PAD have widespread arterial disease and, therefore, are at a significantly increased risk of stroke, myocardial infarction (MI), and cardiovascular death.[@ref1] The prevalence of coronary artery disease (CAD) and cerebrovascular disease (CVD) in these patients can reach 92% and 50%, respectively.[@ref2][@ref3] CAD is the most common cause of death in PAD patients, accounting for 40% to 60% of deaths, while stroke accounts for 10% to 20% of deaths.[@ref1] Furthermore, patients with PAD have a sixfold-increased risk of cardiovascular disease mortality compared to patients without PAD.[@ref4]

The risk factors for PAD are the same as those for atherosclerosis in general and include gender predilection (males at greater risk), advanced age, cigarette smoking, hypertension, diabetes mellitus, and hyperlipidemia.[@ref5] Atherosclerotic risk factor identification and modification plays an important role in reducing the number of adverse outcomes among patients with atherosclerosis. Risk reduction therapy decreases the risk of cardiovascular mortality and morbidity in patients with PAD,[@ref6]--[@ref11] and is comprised of methods such as smoking cessation, blood sugar control, blood pressure control, and medical intervention by antiplatelets, statins, and angiotensin-converting enzyme (ACE) inhibitors. Because of the efficacy of these techniques, several expert committees have recommended their use in patients with PAD.[@ref12]--[@ref14] Despite this, several studies have documented the underuse of risk reduction therapies in patients with PAD.[@ref15]--[@ref23]

The aim of this study was to explore the extent to which risk factors were managed, in accordance with the current recommendations of the American Heart Association and American College of Cardiology (AHA/ACC) for patients with PAD, which are highlighted in **[Table 1](#T1){ref-type="table"}**.[@ref12][@ref14]

###### 

Current recommendations of the American Heart Association and American College of Cardiology (AHA/ACC) for risk reduction in patients with peripheral arterial disease[@ref12][@ref14]
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PATIENTS AND METHODS {#sec1-1}
====================

We prospectively collected data on the atherosclerotic risk factors and risk reduction therapies on consecutive PAD patients who were referred to the vascular surgery outpatient clinic at Toronto General Hospital, Toronto, Canada, between July 2004 and July 2006. This study was approved by the University Health Network Ethics Review Board in Toronto. Patients were defined as having PAD if they had previously undergone lower limb revascularization (bypass surgery and/or percutaneous transluminal angioplasty \[PTA\]) or a lower limb amputation for lower limb ischemia, or had received a clinical diagnosis of intermittent claudication, ischemic rest pain, or tissue loss in conjunction with ankle brachial index (ABI) \<0.9.

We collected data on the following atherosclerotic risk factors: age, gender, family history, smoking habits (current and former), diabetes mellitus (defined as a fasting blood sugar (FBS) \>7 mmol/L when measured on two separate occasions), hypertension (defined as systolic blood pressure \[BP\] \>140 mm Hg and/or diastolic BP \>90 mm Hg), hyperlipidemia (defined as a low-density lipoprotein cholesterol level (LDL-C) \>2.5 mmol/L and/or triglyceride levels (TG) \>1.7 mmol/L), and being overweight (defined as having a body mass index \[BMI\] \>25 kg/m^2^) or obese (BMI \>30 kg/m^2^). In addition, HbA1c was measured in diabetic patients to assess whether they had achieved optimal control for diabetes. We also investigated the use of the following risk reduction pharmacotherapies: antiplatelet medications (e.g., aspirin and clopidegrol), statins, ACE inhibitors, oral hypoglycemic medications, insulin, and antihypertensive medications. Finally, we noted whether patients had any co-morbidities, such as a history of coronary artery disease (CAD), cerebrovascular disease (CVD), and any other major diseases.

Values were expressed as frequencies and percentages, for categorical variables, and as means and standard deviations (SD), for continuous variables. Chi-square tests t tests were used, where appropriate, to make comparisons between groups. All reported P values are two tailed. Significance was defined as *P*\<.05.

RESULTS {#sec1-2}
=======

Data was collected on 391 PAD patients. Baseline characteristics are shown in **[Table 2](#T2){ref-type="table"}**. The mean (SD) number of atherosclerotic risk factors was 3 (1). Hypercholesterolemia was diagnosed in 29.7% (116/391) patients, and hypertriglyceridemia in 40% (157/391) patients. Overall, patients did not adequately control their atherosclerotic risk factors (**[Table 3](#T3){ref-type="table"}**). Of the 56.8% (222/391) of patients with hypertension, only 37.4% (83/222) had adequate blood pressure control (e.g., had BP \<140/90 mm Hg). Furthermore, among patients who were not known to have hypertension, 67.5% (114/169) had BP \>140/90 mm Hg, as measured on two separate occasions at the clinic. Therefore, 64.7% of patients (253/391) either had inadequately-controlled (35.5%) or undiagnosed (29.2%) hypertension.

###### 

Baseline characteristics of peripheral arterial disease patients (n=391).
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###### 

Achievement of the current recommendations of the American Heart Association and American College of Cardiology (AHA/ACC) for control of atherosclerotic factors in patients with peripheral arterial disease in the study.
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The prevalence of DM was 35% (137/391). Of the affected patients, only 49% (67/137) had properly controlled blood sugar (HbA1c \<7%). Furthermore, among patients who were not known to have diabetes, 26.8% (68/254) exhibited an abnormal blood glucose level (FBS \>6 mmol/L). Statins were currently prescribed in 61% (238/391) of patients. Despite this, 38.7% of statin-users continued to have LDL \>2.5 mmol/L. Among non-statin users, this rate was even higher (76.5%; *P*\<.001). Mean LDL level was significantly lower in statin users (2.31 \[0.90\] mmol/L) than in non-statin users (2.92 \[0.96\] mmol) (*P*\<.01). The majority of patients (72.4%; 283/391) were either overweight (64.3%, 182/283; BMI 25-29.9 kg/m^2^) or obese (35.7%, 101/283; BMI \>29.9 kg/m^2^). Although many patients (67.3%; 263/391) were nonsmokers, 73.4% (193/263) of these individuals were former smokers.

Antiplatelets were prescribed for 78.3% (306/391) of patients, of whom 70.6% (216/306) were taking aspirin, 15.3% (47/306) were taking clopidogrel, 8.8% (27/306) were taking a combination of aspirin and clopidegrol, and 5.2% (16/306) were taking other agents. ACE inhibitors were prescribed for 44.8% (175/391) of patients, of whom 82.3% (144/175) were on ramipril. However, only 36.8% (53/144) of ramipril users were taking the optimal dose of 10 mg/day.[@ref9]

DISCUSSION {#sec1-3}
==========

Data was collected prospectively on 391 patients who were referred to a vascular surgery outpatient clinic at a tertiary care hospital. Based on the results of our analyses, we have suggested strategies to further increase the use of risk factor managing strategies.

Atherosclerosis is the leading cause of death worldwide.[@ref24] PAD is a marker of advanced atherosclerosis and indicates an elevated risk of cardiovascular mortality and morbidity comparable to patients with coronary artery disease (CAD).[@ref25] Thus, intensive risk reduction therapy is critical in PAD patients. Therapeutic methods include blood pressure control and risk reduction pharmacotherapy (antiplatelets, statins, and ACE inhibitors), which have been proven to reduce the risk of cardiovascular mortality and morbidity of PAD patients in large-scale randomized clinical trials.[@ref9][@ref11][@ref26] Large observational studies have also shown that smoking cessation and blood sugar control help reduce adverse cardiovascular outcomes in patients with atherosclerosis.[@ref6]--[@ref8] Based on this evidence, several expert cardiovascular panels, including the AHA/ACC and the Canadian Cardiovascular Society, have recommended the use of intensive risk factor control in PAD patients ([Table 1](#T1){ref-type="table"}).[@ref12]--[@ref14] We found that many patients were not treated with optimal risk reduction therapy methods, and that, as a result, risk factors were inadequately controlled and risk factor goals were not achieved. For instance, we noted a deficiency in prescription of risk reduction pharmacotherapies.

Our study is not the first to provide data that support a care gap in managing patients with PAD (**[Table 4](#T4){ref-type="table"}**). The inequities in the use of risk reduction therapies between patients with PAD and those with CAD in which the risk reduction should be similar have been well documented in the literature.[@ref27] We hope that these data will be useful in supporting a call-to-action for PAD management and public awareness.[@ref27] There are several possible explanations for our findings. First, the association of PAD and CAD is usually unrecognized by both patients and primary care physicians,[@ref28] and a significant number of patients with PAD may not have symptoms related to their CAD.[@ref15] Second, there may be gaps between what physicians know they should do, and what they actually do, to manage risk factors in patients with PAD.[@ref29]--[@ref31] Third, there may be a reluctance to apply CAD guidelines to the PAD patient population even though the risks are similar, if not higher.

###### 

Comparison of compliance with risk factor control recommendations among patients in the current study and previously-published studies.
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We admit that this study had some limitations. First, a relatively small number of participants were included in this study. Second, this study reflects the techniques of physicians in one geographic area and therefore may not be generalizable to other locations. However, the validity of these results is strengthened by the prospective nature of our data collection methods.

In conclusion, there is a high prevalence of atherosclerotic risk factors in patients with PAD. However, these individuals are receiving inadequate risk factor management therapies, and/or are not meeting risk factor control goals even when they are receiving treatment. In order to address this care gap, it is vital to develop effective strategies to encourage health professionals to comply with the current guidelines for cardiovascular risk reduction in PAD patients. These may include methods such as self-audit of practice, focused continuing medical education programs, and educational outreach programs.
